DBP.B: Revenues rose and losses narrowed as SI053 clinical trial preparations were completed

About this update from Double Bond Pharmaceutical International Ab Class B

Q1 2025 saw Double Bond Pharmaceutical increase revenues and reduce losses, while finalizing clinical trial preparations for SI053 and extending its Vivo Biopharma partnership. Accounting changes improved equity, but US market uncertainties remain. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Double Bond Pharmaceutical International Ab Class B